---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-007719"
form_type: "8-K"
ticker: "AEMD"
cik: "0000882291"
company_name: "AETHLON MEDICAL INC"
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T21:52:36.504760+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aethlon reports Q2 net loss $3.8M; terminates COVID trial, launches Australia sub

## Summary
- Cash balance $19.6M as of Sep 30, 2022; operating expenses $3.67M, up 71% YoY.
- Terminated US COVID trial due to scarce ICU patients; expects $5M savings over 12 months.
- Launched wholly owned Australian subsidiary in Oct 2022 to conduct oncology studies.
- Dissolved Exosome Sciences, Inc., recording $142K non-cash charge in Q2.
- Raised ~$8.9M net proceeds from ATM stock sales in H1 fiscal 2023.

## SEC filing metadata
- accession: 0001683168-22-007719
- form_type: 8-K
- ticker: AEMD
- cik: 0000882291
- company_name: AETHLON MEDICAL INC
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882291/000168316822007719/0001683168-22-007719-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882291/000168316822007719/aethlon_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-007719
- JSON: https://secwatch.observer/filing/0001683168-22-007719.json
- Plain text: https://secwatch.observer/filing/0001683168-22-007719.txt

## Key facts
- Earnings Releases
  AETHLON MEDICAL INC reported its second quarter ended September 30, 2022 results: net income approximately $3.8 million.
  - Period: its second quarter ended September 30, 2022
  - Net income: approximately $3.8 million
  - Result: reported results
  source text: As a result of the changes in revenues and expenses noted above, our net loss increased to approximately $3.8 million in the three months ended September 30, 2022, from approximately $2.0 million in the three months ended September 30, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882291/000168316822007719/0001683168-22-007719-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.